- Reference code :
- wf292
- Published date :
-
27 October 1999
- Expired date :
-
14 March 2027
AstraZeneca today announced the partial divestment of two cardiovascular medicines, in Scandinavian and European markets, to comply with European Commission merger conditions set in approving the merger of Astra, of Sweden, and Zeneca, of the UK, earlier this year.
Searle, the pharmaceutical sector of Monsanto Company, has purchased exclusive rights throughout the EEA to the product 'seloken Comp', (known as Beloc ZOC Comp. in Germany) a fixed combination of the beta blocker metoprolol and the diuretic hydrochlorthiazide.
AstraZeneca has also sold to Searle distribution rights to the beta blocker product 'Tenorminx', containing atenolol, in Sweden and Norway, in compliance with the merger conditions set out by the Commission. AstraZeneca has extended such distribution rights to Searle to cover 'Tenormin' in Denmark and Finland, and the beta blocker combination product 'Tenoretic' in Denmark.
Financial details were not disclosed and the deal represents less than one per cent of AstraZeneca PLC's net assets.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
